Unplanned excision of synovial sarcomas did not significantly affect 5-year disease-specific survival compared to planned excision (73% vs. 64%, p=0.159).
Cohort (n=90)
Yes
Does unplanned excision affect oncological outcomes in patients with synovial sarcoma compared to planned excision?
Unplanned excision of synovial sarcomas is associated with distinct clinical characteristics but does not significantly worsen long-term oncological outcomes compared to planned excision when followed by appropriate re-excision.
Absolute Event Rate: 73% vs 64%
p-value: p=0.159
BACKGROUND: We aimed to describe the clinical characteristics and outcomes of unplanned excisions of synovial sarcomas. METHODS: In total, 90 patients with synovial sarcomas in the extremities were retrospectively reviewed. Patients were divided into unplanned excision (n = 38) and planned excision (n = 52) groups. The average follow-up period was 6 years. The clinicopathological characteristics and oncologic outcomes were compared. RESULTS: The unplanned excision group showed longer duration of symptoms before diagnosis (p = 0.023), smaller lesion dimensions (p = 0.001), superficial location (p = 0.049), and predilection in the upper extremities (p = 0.037). Synovial sarcomas were most commonly misdiagnosed as neurogenic tumors (56%) in the upper extremities or as cystic masses (47%) in the lower extremities. Oncological outcomes, including disease-specific survival, metastasis-free survival, or local recurrence were not significantly different between the 2 groups (p = 0.159, p = 0.444, and p = 0.335, respectively). Repeated unplanned excision (p = 0.012) and delayed re-excision (p = 0.038) were significant risk factors for local recurrence in the unplanned excision group. CONCLUSIONS: Synovial sarcomas treated with unplanned excision had distinct characteristics. These findings are important for developing diagnostic and therapeutic strategies for synovial sarcoma.
Choi et al. (Thu,) conducted a cohort in Synovial sarcoma (n=90). Unplanned excision vs. Planned excision was evaluated on 5-year disease-specific survival (p=0.159). Unplanned excision of synovial sarcomas did not significantly affect 5-year disease-specific survival compared to planned excision (73% vs. 64%, p=0.159).